Envíos recientes

Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023

Dennett, S.; Mello, E.; Holton, J.; Lai, Xiaoran; Villacampa Javierre, Guillermo; Kilburn, Lucy (Elsevier, 2024-06-25)

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Stojanovic, Goran; Spigel, David; Dowlati, Afshin; NAVARRO, ALEJANDRO; Yang, James Chih-Hsin; Chen, Yuanbin (American Society of Clinical Oncology, 2024-07-01)

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Budde, Lihua; Assouline, Sarit; Sehn, Laurie; Schuster, Stephen; Yoon, Sung-Soo; Yoon, Dok Hyun; Bosch, Francesc (American Society of Clinical Oncology, 2024-07-01)

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

Serrano Sanz, Guillermo; Berastegui Zufiaurre, Nerea; Díaz-Mazkiaran, Aintzane; García-Olloqui, Paula; Rodriguez-Res, Carmen; Huerga-Dominguez, Sofia; Acha, Pamela; Molero , Antonieta; MONTORO, JULIA; VALCARCEL, DAVID (Nature Portfolio, 2024-06-20)

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Mosele, Maria; Stenzinger, Albrecht; Bayle, Arnaud; Bieche, Ivan; Westphalen, Benedikt; Barlesi, Fabrice; Dienstmann, Rodrigo; Serrano, Cesar; Mateo, Joaquin (Elsevier, 2024-07)

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023 ﻿

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer ﻿

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study ﻿

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide ﻿

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group ﻿

Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group